<span>Preclinical Models of Multiple Myeloma</span>
May 9, 2017

Preclinical Models of Multiple Myeloma

AACR Hematologic Malignancies Conference 2017 -- Multiple myeloma is a clonal B cell malignancy characterized by the accumulation of terminally differentiated, antibody-producing plasma cells in the bone marrow that is invasive and drug resistant. Patients are generally asymptomatic until very late state disease.

Read more »
<span>Assessment of Abuse Liability of Brain-Penetrant Compounds: Regulatory Environment, Challenges and Opportunities in View of the Current Opioid Epidemic</span>
May 12, 2017

Assessment of Abuse Liability of Brain-Penetrant Compounds: Regulatory Environment, Challenges and Opportunities in View of the Current Opioid Epidemic

Abuse liability of a drug refers to its potential use in a non-medical situation for the positive psychoactive effects it produces through its Central Nervous System (CNS) activity.The assessment of the abuse liability/potential of a drug encompasses all properties of the drug (chemical, pharmacological, pharmacokinetics, usage and diversion history), and
Read more »
<span>covance - kit production-INFCLS004</span>
May 19, 2017

covance - kit production-INFCLS004

Not all kits are created equal. Accurate, on-time kits matter. Meet your clinical study milestones with uninterrupted visits. Covance has the scalability to meet your largest or smallest clinical trial needs. We produce more clinical trial kits than any other central laboratory.
Read more »
<span>How to Maximize Patient Recruitment in Oncology Trials</span>
June 6, 2017

How to Maximize Patient Recruitment in Oncology Trials

Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of drug development programs. This article highlights unique expertise, tools and other attributes that can help companies excel in oncology clinical trials.
Read more »